Peter A McArdle1, Tahir Qayyum, Donald C McMillan. 1. University Department of Surgery, Faculty of Medicine, University of Glasgow, Royal Infirmary, Glasgow, UK. peters @ doctors.org.uk
Abstract
AIM: To examine the prognostic value of circulating C-reactive protein concentrations at diagnosis in patients with organ-confined prostate cancer. PATIENTS AND METHODS: Ninety-eight patients with histologically proven clinically localised prostate cancer were studied. Clinical stage, tumour grade, circulating PSA and C-reactive protein concentrations at diagnosis were recorded. RESULTS: The majority of patients was under the age of 70 years and had low-grade tumours. Approximately half the patients received radical local treatment. During the follow-up period (median 10 years) 38 patients died, of whom 18 died of prostate cancer, 6 of other cancers and 14 of non-cancer causes. On univariate survival analysis, age (p < 0.001), Gleason score (p < 0.05), C-reactive protein (p < 0.05) and treatment (p < 0.05) were significant predictors of overall survival. On univariate survival analysis, age (p < 0.001), Gleason score (p < 0.05) and C-reactive protein (p < 0.05) were significant predictors of prostate cancer-specific survival. On multivariate analysis of these significant variables age (HR 4.88, 95% CI 1.79-13.29, p < 0.01), Gleason score (HR 2.16, 95% CI 1.23-3.78, p < 0.01) and C-reactive protein (HR 1.88, 95% CI 1.01-3.52, p < 0.05) remained significant independent predictors of prostate cancer-specific survival. CONCLUSION: The results of the present study show that the presence of a systemic inflammatory response, at diagnosis, independently predicts poor long-term cancer outcome in patients with localised prostate cancer. Copyright (c) 2010 S. Karger AG, Basel.
AIM: To examine the prognostic value of circulating C-reactive protein concentrations at diagnosis in patients with organ-confined prostate cancer. PATIENTS AND METHODS: Ninety-eight patients with histologically proven clinically localised prostate cancer were studied. Clinical stage, tumour grade, circulating PSA and C-reactive protein concentrations at diagnosis were recorded. RESULTS: The majority of patients was under the age of 70 years and had low-grade tumours. Approximately half the patients received radical local treatment. During the follow-up period (median 10 years) 38 patients died, of whom 18 died of prostate cancer, 6 of other cancers and 14 of non-cancer causes. On univariate survival analysis, age (p < 0.001), Gleason score (p < 0.05), C-reactive protein (p < 0.05) and treatment (p < 0.05) were significant predictors of overall survival. On univariate survival analysis, age (p < 0.001), Gleason score (p < 0.05) and C-reactive protein (p < 0.05) were significant predictors of prostate cancer-specific survival. On multivariate analysis of these significant variables age (HR 4.88, 95% CI 1.79-13.29, p < 0.01), Gleason score (HR 2.16, 95% CI 1.23-3.78, p < 0.01) and C-reactive protein (HR 1.88, 95% CI 1.01-3.52, p < 0.05) remained significant independent predictors of prostate cancer-specific survival. CONCLUSION: The results of the present study show that the presence of a systemic inflammatory response, at diagnosis, independently predicts poor long-term cancer outcome in patients with localised prostate cancer. Copyright (c) 2010 S. Karger AG, Basel.
Authors: Tahir Qayyum; Peter McArdle; Mustafa Hilmy; James Going; Clare Orange; Morag Seywright; Paul Horgan; Mark Underwood; Joanne Edwards Journal: Curr Urol Date: 2013-02-08
Authors: S Sevcenco; R Mathieu; P Baltzer; T Klatte; H Fajkovic; C Seitz; P I Karakiewicz; M Rouprêt; M Rink; L Kluth; Q-D Trinh; W Loidl; A Briganti; D S Scherr; S F Shariat Journal: Prostate Cancer Prostatic Dis Date: 2016-01-26 Impact factor: 5.554
Authors: Keefe Murphy; Brendan T Murphy; Susie Boyce; Louise Flynn; Sarah Gilgunn; Colm J O'Rourke; Cathy Rooney; Henning Stöckmann; Anna L Walsh; Stephen Finn; Richard J O'Kennedy; John O'Leary; Stephen R Pennington; Antoinette S Perry; Pauline M Rudd; Radka Saldova; Orla Sheils; Denis C Shields; R William Watson Journal: Mol Oncol Date: 2018-08-07 Impact factor: 6.603